Long-Term Benzodiazepine Use in Elderly Patients with Chronic Anxiety
Eleven years of stable diazepam runs into a new fall and a new finding on cognitive screening. The debate is no longer whether to taper, but how to do it safely in a 74-year-old living alone.
Walter S., a 74-year-old retired accountant, has generalized anxiety disorder dating back to his fifties and has taken diazepam 5 mg twice daily for the last eleven years, prescribed originally by a physician who has since retired. He lives alone since his wife's death two years ago, drives himself to appointments, and has had one fall in the past six months — a stumble on stairs he attributes to a loose rug, without loss of consciousness or injury requiring evaluation. His most recent cognitive screening, done at this visit, shows mild impairment on delayed recall not previously documented.
Diazepam's long half-life and active metabolites make it a particularly poor choice for ongoing use in an elderly patient by current standards, carrying real, dose-related risk for both falls and cognitive impairment that compounds with age and duration of use — the new delayed-recall finding, even if mild and possibly multifactorial, is exactly the kind of signal that should prompt real reconsideration rather than routine renewal. Against that is eleven years of anxiety control this patient has never had to question, and a taper attempt in a long-term benzodiazepine user, especially one this old and living alone, carries genuine withdrawal risk of its own, including seizure risk if done carelessly.
Walter himself is candid that he's never questioned the prescription in eleven years and assumed, reasonably enough given how long it's been renewed without incident, that it must still be the right choice — he's surprised, not defensive, to hear the medication itself might be contributing to the fall and the new cognitive finding, and says he wants to understand the reasoning rather than simply be told what to do.
Planning a taper after 11 years
Diazepam specifically, given its long half-life and active metabolites, is one of the worst-suited benzodiazepines for continued use at his age — the new delayed-recall finding and the recent fall are both plausibly related, even though neither is proven to be caused by the drug alone. This is a real signal to act on, not just monitor.
A taper is the right direction, but the pace matters enormously in an eleven-year user — too fast risks withdrawal seizures, especially given diazepam's own long half-life somewhat protecting against abrupt symptom onset but not against a truly rushed reduction. A cross-taper to a shorter-acting agent isn't obviously safer here and adds its own complexity; a slow, direct diazepam taper over several months, with close monitoring, is the more conservative path.
Given he lives alone, I'd want a structured plan with explicit check-ins, not just a prescription change handed to him at this visit — a home safety assessment given the fall, cognitive reassessment partway through the taper to see if the delayed-recall finding improves as the diazepam dose comes down, and a clear understanding with him that this is a gradual, monitored process, not an abrupt stop.
Agreed: a slow diazepam taper over several months with buspirone added for the underlying anxiety — explicitly not as withdrawal cover, since it has no benzodiazepine cross-tolerance and will not blunt withdrawal, and since response to it is often blunted in recent benzodiazepine users — a home safety assessment arranged given the recent fall, and cognitive reassessment scheduled partway through the taper.